| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bausch Health Companies Inc.$4.77
+0.01 (+0.21%)
B 77Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.87 B
EPS
-3.19
P/E Ratio
-1.57 $
Value Trade
12.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.52 B
R&D Expenses
163.00 M
Operating CF
230.00 M
Total Assets
24.50 B
Total Liabilities
25.58 B
Equity
-2.06 B
D/E Ratio
12,345
0.55 %
Week
-5.36 %
1 Month
-8.07 %
3 Month
-8.83 %
6 Month
-82.79 %
5 Year
994.01 %
All Time
Cash Data
Cash Position
1.31 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
4.41 M
52 Week Range
4.54 - 8.69
% held by Insiders
11.56 %
% held by Institutions
67.82 %
Enterprise Value
22.40 B
Total Shares
372.58 M
Short %
2.34 %
Float Shares
262.07 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B77
Pipeline Score $16.3B
Pipeline ValueUndervalued
Valuation Signal46
Drugs Scored15.0x
rNPV / MCap Top 97%
Micro Cap (rank 28 of 905)
Percentile RankBausch Health Companies Inc. holds a solid B-grade pipeline (77/100), with $40.8B risk-adjusted pipeline value, led by Rifaximin in Diarrhea (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| open-label rifaximin Small molecule | Irritable Bowel Syndrome With Diarrhea | Phase 3 | NCT01543178 | 49% | $5.4B | COMPLETED | 2,583 | - | - | Jun 1, 2014 | - | Dec 12, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Larsucosterol | alcoholic hepatitis | Phase 2b | 2025-07-30 | |||
Larsucosterol | alcoholic hepatitis | Phase 2b | 2025-07-30 | |||
Larsucosterol | alcoholic hepatitis | Phase 2b | 2025-07-30 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BHC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BHC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-26 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-26 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-26 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BHCBausch Health’s Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Solta Medical has received the AAA Well-Known Trademark Certification for its Thermage® brand in China, a prestigious recognition awarded to only 217 brands. This certification highlights Thermage's strong brand reputation and consumer confidence in the non-invasive aesthetic treatment market. The CEO emphasized the importance of this accolade in reinforcing trust among consumers and practitioners.
Read more →BHCBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Solta Medical has achieved the AAA Well-Known Trademark Certification for Thermage® in China, a significant recognition awarded to only 217 brands. This certification underscores Thermage's strong brand reputation and consumer confidence in the non-invasive aesthetic treatment market. The CEO highlighted this achievement as a testament to their commitment to quality and innovation.
Read more →BHCBausch Health Announces 2026 Annual Meeting of Shareholder Results
Bausch Health Companies Inc. announced the successful election of all 10 director nominees during its 2026 Annual Meeting of Shareholders. Notably, Dr. Eiry W. Roberts was elected as a new director, bringing extensive experience in pharmaceutical leadership. Shareholders also approved the compensation for named executive officers and the appointment of PricewaterhouseCoopers LLP as the auditor.
Read more →BHCBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
Bausch Health Companies Inc. will participate in the RBC Capital Markets 2026 Global Healthcare Conference on May 20, 2026. CEO Thomas J. Appio and CFO Jean-Jacques Charhon will engage in a fireside chat, which will be available via a live audio webcast. A replay will also be accessible post-event.
Read more →BHCBausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
Bausch Health Companies Inc. will participate in the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026. Company management will engage in a fireside chat, which will be accessible via a live audio webcast. A replay will also be available post-event, emphasizing the company's commitment to investor relations.
Read more →BHCBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
Bausch Health's Ortho Dermatologics has launched Biafine®, a skincare emulsion, available through select online channels in the U.S. This iconic French product, known for its ability to support skin hydration and barrier function, has been trusted by dermatologists since its introduction in 1971. The launch aims to provide easier access for patients and dermatology practices.
Read more →BHCBausch Health to Announce First Quarter 2026 Results on April 29, 2026
Bausch Health Companies Inc. will release its first quarter 2026 financial results on April 29, 2026. A live conference call will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. The investor relations materials will be available prior to the call.
Read more →BHCBausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
Bausch Health has launched the 2026 ASPIRE HIGHER Scholarship Program to assist six students affected by dermatologic conditions. Each scholarship will provide up to $10,000 for higher education. Applications are open until June 10, 2026, and recipients will be notified in July 2026. The program aims to recognize the achievements of these students and the healthcare providers supporting them.
Read more →BHCBausch Health Provides Update on RED-C Phase 3 Clinical Trials
Bausch Health announced the results of its Phase 3 RED-C clinical trials, which evaluated amorphous-rifaximin SSD for preventing hepatic encephalopathy in liver cirrhosis patients. Despite being safe and well-tolerated, the trials failed to meet their primary endpoint. The company is reviewing the data for potential new development opportunities.
Read more →BHCBausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
Bausch Health Companies Inc. will release its fourth quarter and full year 2025 financial results on February 18, 2026. The announcement will be followed by a live conference call at 5:00 p.m. U.S. EST to discuss the results and provide a business update. Investors can access materials on the company's website prior to the call.
Read more →BHCBausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026. CEO Thomas J. Appio, along with other executives, will attend the event in San Francisco. A live audio webcast will be available, and a replay will follow on their investor relations website.
Read more →Competitive Position
How BHC ranks across every disease it competes inCompetitive Position is a premium feature
See how BHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial